The results of the current study identified seven target genes of dehydrovomifoliol in NAFLD treatment, namely E2F1, MERTK, SOX17, MMP9, SULT2A1, VEGFA, and BLVRA. This evidence concerns the gene E2F1 and metabolic dysfunction-associated steatotic liver disease.